Literature DB >> 15931382

Lessons learned from cancer may help in the treatment of pulmonary hypertension.

Serge Adnot1.   

Abstract

Hyperplasia of pulmonary artery SMCs (PASMCs) is a pathological hallmark of pulmonary arterial hypertension (PAH). In this issue of the JCI, McMurtry et al. report that adenovirus-mediated overexpression of survivin--a multipotent inhibitor of apoptosis--induces PAH in rats, whereas inhalation of an adenovirus vector encoding a mutant survivin gene with dominant-negative properties reverses established monocrotaline-induced PAH. These findings raise important issues regarding the role of survivin in the pathogenesis of PAH, its value as a prognostic indicator, and its use as a target for new therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15931382      PMCID: PMC1137011          DOI: 10.1172/JCI25399

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  18 in total

Review 1.  Validating survivin as a cancer therapeutic target.

Authors:  Dario C Altieri
Journal:  Nat Rev Cancer       Date:  2003-01       Impact factor: 60.716

2.  Reversibility of caspase activation and its role during glycochenodeoxycholate-induced hepatocyte apoptosis.

Authors:  Kewei Wang; John J Brems; Richard L Gamelli; Jinwen Ding
Journal:  J Biol Chem       Date:  2005-03-14       Impact factor: 5.157

3.  Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy.

Authors:  J Kato; Y Kuwabara; M Mitani; N Shinoda; A Sato; T Toyama; A Mitsui; T Nishiwaki; S Moriyama; J Kudo; Y Fujii
Journal:  Int J Cancer       Date:  2001-03-20       Impact factor: 7.396

4.  Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension.

Authors:  S D Lee; K R Shroyer; N E Markham; C D Cool; N F Voelkel; R M Tuder
Journal:  J Clin Invest       Date:  1998-03-01       Impact factor: 14.808

5.  Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene.

Authors:  Z Deng; J H Morse; S L Slager; N Cuervo; K J Moore; G Venetos; S Kalachikov; E Cayanis; S G Fischer; R J Barst; S E Hodge; J A Knowles
Journal:  Am J Hum Genet       Date:  2000-07-20       Impact factor: 11.025

6.  Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension.

Authors:  M Sean McMurtry; Stephen L Archer; Dario C Altieri; Sebastien Bonnet; Alois Haromy; Gwyneth Harry; Sandra Bonnet; Lakshmi Puttagunta; Evangelos D Michelakis
Journal:  J Clin Invest       Date:  2005-06       Impact factor: 14.808

7.  Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension.

Authors:  K B Lane; R D Machado; M W Pauciulo; J R Thomson; J A Phillips; J E Loyd; W C Nichols; R C Trembath
Journal:  Nat Genet       Date:  2000-09       Impact factor: 38.330

8.  A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers.

Authors:  M Monzó; R Rosell; E Felip; J Astudillo; J J Sánchez; J Maestre; C Martín; A Font; A Barnadas; A Abad
Journal:  J Clin Oncol       Date:  1999-07       Impact factor: 44.544

9.  Survivin-dependent angiogenesis in ischemic brain: molecular mechanisms of hypoxia-induced up-regulation.

Authors:  Edward M Conway; Femke Zwerts; Veerle Van Eygen; Astrid DeVriese; Nobuo Nagai; Wei Luo; Désiré Collen
Journal:  Am J Pathol       Date:  2003-09       Impact factor: 4.307

10.  Serotonin-induced smooth muscle hyperplasia in various forms of human pulmonary hypertension.

Authors:  Elisabeth Marcos; Elie Fadel; Olivier Sanchez; Marc Humbert; Philippe Dartevelle; Gerald Simonneau; Michel Hamon; Serge Adnot; Saadia Eddahibi
Journal:  Circ Res       Date:  2004-04-01       Impact factor: 17.367

View more
  14 in total

Review 1.  Pulmonary arterial hypertension associated with systemic sclerosis.

Authors:  Stephen C Mathai; Paul M Hassoun
Journal:  Expert Rev Respir Med       Date:  2011-04       Impact factor: 3.772

Review 2.  Lung involvement in systemic sclerosis.

Authors:  Paul M Hassoun
Journal:  Presse Med       Date:  2010-12-30       Impact factor: 1.228

3.  Effects of HIV protease inhibitors on progression of monocrotaline- and hypoxia-induced pulmonary hypertension in rats.

Authors:  Guillaume Gary-Bobo; Amal Houssaini; Valerie Amsellem; Dominique Rideau; Pierre Pacaud; Aline Perrin; Jérémy Brégeon; Elisabeth Marcos; Jean-Luc Dubois-Randé; Olivier Sitbon; Laurent Savale; Serge Adnot
Journal:  Circulation       Date:  2010-10-25       Impact factor: 29.690

4.  Delineating the angiogenic gene expression profile before pulmonary vascular remodeling in a lamb model of congenital heart disease.

Authors:  Jing Tian; Sohrab Fratz; Yali Hou; Qing Lu; Agnes Görlach; John Hess; Christian Schreiber; Sanjeev A Datar; Peter Oishi; John Nechtman; Robert Podolsky; Jin-Xiong She; Jeffrey R Fineman; Stephen M Black
Journal:  Physiol Genomics       Date:  2010-10-26       Impact factor: 3.107

Review 5.  Therapy for pulmonary arterial hypertension associated with systemic sclerosis.

Authors:  Stephen C Mathai; Paul M Hassoun
Journal:  Curr Opin Rheumatol       Date:  2009-11       Impact factor: 5.006

6.  Therapies for scleroderma-related pulmonary arterial hypertension.

Authors:  Paul M Hassoun
Journal:  Expert Rev Respir Med       Date:  2009       Impact factor: 3.772

7.  A dosing/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension.

Authors:  M Gomberg-Maitland; M L Maitland; R J Barst; L Sugeng; S Coslet; T J Perrino; L Bond; M E Lacouture; S L Archer; M J Ratain
Journal:  Clin Pharmacol Ther       Date:  2009-12-09       Impact factor: 6.875

8.  Rapamycin reverses pulmonary artery smooth muscle cell proliferation in pulmonary hypertension.

Authors:  Amal Houssaini; Shariq Abid; Nathalie Mouraret; Feng Wan; Dominique Rideau; Mirna Saker; Elisabeth Marcos; Claire-Marie Tissot; Jean-Luc Dubois-Randé; Valérie Amsellem; Serge Adnot
Journal:  Am J Respir Cell Mol Biol       Date:  2013-05       Impact factor: 6.914

Review 9.  Pulmonary arterial hypertension in connective tissue diseases.

Authors:  Stephen C Mathai; Paul M Hassoun
Journal:  Heart Fail Clin       Date:  2012-07       Impact factor: 3.179

10.  Induction of microRNA-221 by platelet-derived growth factor signaling is critical for modulation of vascular smooth muscle phenotype.

Authors:  Brandi N Davis; Aaron C Hilyard; Peter H Nguyen; Giorgio Lagna; Akiko Hata
Journal:  J Biol Chem       Date:  2008-12-15       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.